<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A6F3A59B-CC61-4222-B76C-63C7CC119707"><gtr:id>A6F3A59B-CC61-4222-B76C-63C7CC119707</gtr:id><gtr:name>UC Davis Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A6F3A59B-CC61-4222-B76C-63C7CC119707"><gtr:id>A6F3A59B-CC61-4222-B76C-63C7CC119707</gtr:id><gtr:name>UC Davis Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B75CEAD1-C876-476F-8966-3BABE6C255E9"><gtr:id>B75CEAD1-C876-476F-8966-3BABE6C255E9</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Wride</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F9BA76DD-D8D4-4C19-93AF-F65FF3DDDB23"><gtr:id>F9BA76DD-D8D4-4C19-93AF-F65FF3DDDB23</gtr:id><gtr:firstName>Marcela</gtr:firstName><gtr:surname>Votruba</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A3B9B85D-1FE7-4413-9BD7-9E7D5ACCCCCC"><gtr:id>A3B9B85D-1FE7-4413-9BD7-9E7D5ACCCCCC</gtr:id><gtr:firstName>Mike</gtr:firstName><gtr:surname>Boulton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500790"><gtr:id>3D882F49-3F23-4667-86ED-1063D905BD92</gtr:id><gtr:title>OPA3: a novel gene and mechanism in cataractogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500790</gtr:grantReference><gtr:abstractText>Cataract is due to cloudiness in the lens of the eye and so far, to date, there is no known way to prevent this fronm happening with age. Cataract is the most common cause of visual loss in humans, with at least 25 million blind and 110 million visually impaired world-wide. Despite surgery the number of patients who are blind world-wide increases steadily year on year. Adult cataract has been shown to have an environmental and a genetic component and there are over 20 cataract loci 10 genes for inherited cataracts. Recently, two heterozygous missense mutations in a new gene called OPA3 have been reported in patients with cataract (particularly the blue-dot type) and optic atrophy. The function of the OPA3 protein is not known, but it appears that it is targeted to mitochondria, which are tiny sub-cellular organelles. From what we know of the mechanism of development of the lens of the eye it appears highly likely that the OPA3 gene will prove interesting in the study of cataract formation. The mechanisms of programmed cell death (apoptosis) and the processes by which immature lens fibre cells lose their organelles and nuclei and become transparent are thought to be related. There is some evidence that OPA3 may act in an anti-apoptotic role and therefore it is postulated to be the first gene to cause cataractogenesis by this mechanism. 

We plan to screen blue-dot cataract families and individuals for mutation in OPA3. We also plan to explore the expression of OPA3 in the eye and lens in developing and adult tissue. Lastly, we shall explore the function of OPA3 using cell lines and a mouse model.</gtr:abstractText><gtr:technicalSummary>Missense mutation in the OPA3 gene have recently been shown to cause human cataract, typically blue-dot cataract. This may be congenital or seen in adult patients. We hypothesise that OPA3 is an important gene because its characterisation will better our understanding of lens development and cataractogenesis and it may shed light on some new mechanisms. To test our hypothesis we will screen blue-dot cataract families and individuals for mutation in OPA3. We also hypothesise that OPA3 is expressed in the developing and mature lens and has a key developmental and physiological function. We plan to explore the expression profile of OPA3 in the eye and lens in developing and adult tissue and assess co-localization with mitochondria. Little is know of OPA3 function, save that it is targeted to mitochondrial inner membrane. Lastly, we hypothesise that OPA3 has a role in cataractogenesis by a mechanism which involves mitochondria, either by mitochondrially initiated apoptosis or non-apoptotic signalling in lens cell differentiation. We shall explore this in vitro using cell lines expressing mutant opa3, over-expressing wild type opa3 and use siRNA to knockdown wild type opa3 expression. We shall also explore a new and unique mouse model of mutant opa3, which we are in a position to generate and study rapidly due to preliminary work we have carried out.</gtr:technicalSummary><gtr:fund><gtr:end>2009-07-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-07-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>199999</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biosciences</gtr:department><gtr:description>BIOSI Cardiff TW</gtr:description><gtr:id>F4418DEA-A4C4-42B6-AE1C-D5F54ED8D624</gtr:id><gtr:impact>New grant being written and paper submitted</gtr:impact><gtr:outcomeId>646ACB685C4-1</gtr:outcomeId><gtr:partnerContribution>Unique research skills and knowledge on the metabolic aspects of Opa3 mutation and the associated disease phenotype seen in type III MGA in man and mouse model</gtr:partnerContribution><gtr:piContribution>Opa3 mice, tissues, blood, genotyping, phenotyping data, blood analysis of 3methylglutaconic acids</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UC Davis Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>Uiversity of California Davis Opa3</gtr:description><gtr:id>8E956828-E73C-462B-AE9F-B9A580AE758C</gtr:id><gtr:impact>Abstracts and presentations at meetings in USA</gtr:impact><gtr:outcomeId>411B0D0C6A6-1</gtr:outcomeId><gtr:partnerContribution>Scientific exploration of role of Opa3 in cardiomyopathy</gtr:partnerContribution><gtr:piContribution>Breeding and sampling of Opa3 mutant mice</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F3F79B5A-C155-461A-B06F-A08C7D91F0FE</gtr:id><gtr:impact>Members of the general public and interested parties toured the department and saw results of our research, asking questions.

Interested generated for future event.</gtr:impact><gtr:outcomeId>dNmHR7YrTtz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD student</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Cardiff University</gtr:fundingOrg><gtr:id>5A5A7129-AFAA-4D5E-916D-DF64E49203CA</gtr:id><gtr:outcomeId>EEJa1ytkW591</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD student</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AE80CFB0-8515-4AAC-A00D-63990A9C4B17</gtr:id><gtr:outcomeId>EEJa1ytkW590</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel mutant mouse modelling human 3-MethylGlutaconic aciduria, including optic atrophy.</gtr:description><gtr:grantRef>G0500790</gtr:grantRef><gtr:id>802ECD1F-1F3C-4EFE-9BF7-EDF5C789EE4C</gtr:id><gtr:impact>Non-commercial collaborative research.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>GUirAWr23HL</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>B6;C3-Opa3 L122P mutant mouse</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Novel mutant B6;C3-Opa1 Q285 STOP</gtr:description><gtr:id>7F1C9495-8F99-4D69-B362-35A2AA11247F</gtr:id><gtr:impact>ongoing research</gtr:impact><gtr:outcomeId>BB31D5E4D9E</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Opa1 mutant mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Generated polyclonal anti-Opa3</gtr:description><gtr:id>3FE87F8E-2F7E-4E9C-A3F4-A7AED7695600</gtr:id><gtr:impact>Cell culture studies by third parties</gtr:impact><gtr:outcomeId>cBthh2xHoyn</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>anti-Opa3</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>B6;C3-Opa3 L122P</gtr:description><gtr:id>0B952F76-1FF4-4425-8F15-29C63A38BE7A</gtr:id><gtr:impact>ongoing reearch</gtr:impact><gtr:outcomeId>1D694108F4B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Opa3 mutant mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mutant ~Opa3 mice provide tissues for research and cells for establishing cell lines etc</gtr:description><gtr:id>BC0C7659-D6B1-4911-91A6-1DF329E7D158</gtr:id><gtr:impact>A publication is submitted</gtr:impact><gtr:outcomeId>49475E7D00D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Opa3 mutant mouse and tissues</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New equipment</gtr:description><gtr:id>712DA59D-1036-48DA-B2C1-2F6C762E37A8</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>E9D11B2DAE2</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New -80</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DD61C226-311A-4116-A520-3546ECE45B75</gtr:id><gtr:title>Non-image-forming light driven functions are preserved in a mouse model of autosomal dominant optic atrophy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f09a013088726e70b4910c9114041225"><gtr:id>f09a013088726e70b4910c9114041225</gtr:id><gtr:otherNames>Perganta G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13502_22_23409176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86232A08-471B-4245-92D7-736513BF7194</gtr:id><gtr:title>Opa3, a novel regulator of mitochondrial function, controls thermogenesis and abdominal fat mass in a mouse model for Costeff syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a37a31beccc4d3e788aefd255bdcc1b0"><gtr:id>a37a31beccc4d3e788aefd255bdcc1b0</gtr:id><gtr:otherNames>Wells T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13502_22_22869679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A717A4CB-3D80-41C2-B26A-BA30C77F373D</gtr:id><gtr:title>Changes in corneal collagen architecture during mouse postnatal development.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42d33b2ee545e39599ad62cd006aa8ac"><gtr:id>42d33b2ee545e39599ad62cd006aa8ac</gtr:id><gtr:otherNames>Sheppard J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>AbsbSnNMuAf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47CB3D5F-F12D-4F0E-9EA6-48E4205DEC13</gtr:id><gtr:title>Disrupted mitochondrial function in the Opa3L122P mouse model for Costeff Syndrome impairs skeletal integrity.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a6cd4b0227778c724fc656ee7e668eb"><gtr:id>6a6cd4b0227778c724fc656ee7e668eb</gtr:id><gtr:otherNames>Navein AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>58af0ca0bf1bf3.10448229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F5827D0-EC62-4C5A-9822-8963D3AB3F9B</gtr:id><gtr:title>A missense mutation in the murine Opa3 gene models human Costeff syndrome.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f500f5abf337a398ddd5b15a72dd75"><gtr:id>d6f500f5abf337a398ddd5b15a72dd75</gtr:id><gtr:otherNames>Davies VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>3E2A0528EE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF19821B-BE0F-4F8F-9C40-CCE9FE4D9894</gtr:id><gtr:title>Mitochondrial localization and ocular expression of mutant Opa3 in a mouse model of 3-methylglutaconicaciduria type III.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfc66c14e0688ccc16d1c3a8afd1b4cc"><gtr:id>cfc66c14e0688ccc16d1c3a8afd1b4cc</gtr:id><gtr:otherNames>Powell KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>ZXTunK6eE3T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96F628AB-66AC-4504-86B9-5733539577C2</gtr:id><gtr:title>Clinical and molecular genetic findings in autosomal dominant OPA3-related optic neuropathy.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f12b97dd9cc14f8294a97e4001216bd4"><gtr:id>f12b97dd9cc14f8294a97e4001216bd4</gtr:id><gtr:otherNames>Sergouniotis PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>545cced162d8f8.84687564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAC7D1E7-0501-4962-A77C-6BD6DAC73900</gtr:id><gtr:title>Visual and psychological morbidity among patients with autosomal dominant optic atrophy.</gtr:title><gtr:parentPublicationTitle>Acta ophthalmologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9722f6428465edb963f5cd639e62f91"><gtr:id>a9722f6428465edb963f5cd639e62f91</gtr:id><gtr:otherNames>Bailie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1755-375X</gtr:issn><gtr:outcomeId>pm_13502_22_23452392</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500790</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>